Pro­to­cols: CoLu­cid shares rock­et up on pos­i­tive mi­graine PhI­II; Sage bags a 'break­through' on post-par­tum de­pres­sion

Shares of Cam­bridge, MA-based CoLu­cid Phar­ma­ceu­ti­cals $CLCD soared 90% Tues­day morn­ing af­ter the com­pa­ny de­clared a suc­cess for its Phase III study of the oral mi­graine drug las­mid­i­tan. In­ves­ti­ga­tors say that the drug scored on the pri­ma­ry as well as key sec­ondary end­points in their late-stage study. The pri­ma­ry end­point tracked pa­tients’ ex­pe­ri­ence in the two hours af­ter tak­ing the drug, with the 100 mg and 200 mg dos­ing arms be­ing pain free at rough­ly twice the 15% place­bo re­sponse rate. About a third of all the pa­tients, though, were washed out af­ter fail­ing to qual­i­fy for the mod­i­fied ITT group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER